Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Yankelvitz
Icahn School of Medicine at Mount Sinai, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Cornell Research Foundation
Intellectual property rights (e.g., royalties, patents, copyrights) not from the awardee Institution
Dr. David Yankelevitz (a Co-Investigator in this study) is a named inventor on a number of patents and patent applications relating to the evaluation of diseases of the chest including measurement of nodules. Some of these, which are owned by Cornell Research Foundation (CRF) are non-exclusively licensed to General Electric. As an inventor of these patents, Dr. Yankelevitz is entitled to a share of any compensation which CRF may receive from its commercialization of these patents, the value of which may be affected by the outcome of this study.
Lung Adenocarcinoma Invasion Genomics
The project addresses an important unmet need in the diagnosis and treatment of early stage lung cancer. Recent experience has shown that a large number of lung adenocarcinomas may be biologically and clinically indolent, and that other small early stage tumors may be biologically and clinically aggressive. Our project proposes to identify and validate specific genomic loci that are associated with biology that is indolent or aggressive. Our long term goal is to develop biomarkers that will stratify risk before or after resection of tumors that are similar radiographically or histologically, respectively.
Filed on September 15, 2017.
Tell us what you know about David Yankelvitz's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.